nodes	percent_of_prediction	percent_of_DWPC	metapath
Flutamide—prostate cancer—bone cancer	0.69	1	CtDrD
Flutamide—CYP3A4—bone cancer	0.222	1	CbGaD
Flutamide—CYP1B1—Doxorubicin—bone cancer	0.0119	0.907	CbGbCtD
Flutamide—Metastatic neoplasm—Cisplatin—bone cancer	0.00246	0.0642	CcSEcCtD
Flutamide—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00131	0.0367	CbGpPWpGaD
Flutamide—Metastatic neoplasm—Epirubicin—bone cancer	0.00126	0.033	CcSEcCtD
Flutamide—CYP3A4—Doxorubicin—bone cancer	0.00122	0.0931	CbGbCtD
Flutamide—Metastatic neoplasm—Doxorubicin—bone cancer	0.00117	0.0305	CcSEcCtD
Flutamide—Necrolysis epidermal—Methotrexate—bone cancer	0.00114	0.0298	CcSEcCtD
Flutamide—CYP1B1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0011	0.0307	CbGpPWpGaD
Flutamide—CYP1B1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.001	0.028	CbGpPWpGaD
Flutamide—Proctitis—Epirubicin—bone cancer	0.000991	0.0259	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000971	0.0272	CbGpPWpGaD
Flutamide—Proctitis—Doxorubicin—bone cancer	0.000917	0.024	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—T—bone cancer	0.000906	0.0253	CbGpPWpGaD
Flutamide—Nodule—Methotrexate—bone cancer	0.00088	0.023	CcSEcCtD
Flutamide—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000715	0.02	CbGpPWpGaD
Flutamide—CYP1A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000676	0.0189	CbGpPWpGaD
Flutamide—AR—Nuclear Receptors—NR1I2—bone cancer	0.000655	0.0183	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—FEV—bone cancer	0.000625	0.0175	CbGpPWpGaD
Flutamide—CYP1A1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.000618	0.0173	CbGpPWpGaD
Flutamide—Bullous eruption—Epirubicin—bone cancer	0.000612	0.016	CcSEcCtD
Flutamide—Laboratory test abnormal—Epirubicin—bone cancer	0.000579	0.0151	CcSEcCtD
Flutamide—CYP1B1—Estrogen metabolism—CYP3A4—bone cancer	0.000576	0.0161	CbGpPWpGaD
Flutamide—Bullous eruption—Doxorubicin—bone cancer	0.000566	0.0148	CcSEcCtD
Flutamide—Loss of libido—Methotrexate—bone cancer	0.00056	0.0146	CcSEcCtD
Flutamide—Liver injury—Cisplatin—bone cancer	0.00056	0.0146	CcSEcCtD
Flutamide—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000553	0.0155	CbGpPWpGaD
Flutamide—Laboratory test abnormal—Doxorubicin—bone cancer	0.000536	0.014	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000523	0.0146	CbGpPWpGaD
Flutamide—AR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000517	0.0145	CbGpPWpGaD
Flutamide—CYP1B1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000509	0.0142	CbGpPWpGaD
Flutamide—Ulcer—Cisplatin—bone cancer	0.000498	0.013	CcSEcCtD
Flutamide—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000482	0.0135	CbGpPWpGaD
Flutamide—CYP1B1—Metapathway biotransformation—CYP4V2—bone cancer	0.000472	0.0132	CbGpPWpGaD
Flutamide—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000459	0.0128	CbGpPWpGaD
Flutamide—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000431	0.012	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00043	0.012	CbGpPWpGaD
Flutamide—Transaminases increased—Epirubicin—bone cancer	0.000398	0.0104	CcSEcCtD
Flutamide—CYP1A1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00039	0.0109	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000387	0.0108	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000384	0.0107	CbGpPWpGaD
Flutamide—Haemolytic anaemia—Cisplatin—bone cancer	0.000379	0.0099	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00037	0.0103	CbGpPWpGaD
Flutamide—Transaminases increased—Doxorubicin—bone cancer	0.000368	0.00962	CcSEcCtD
Flutamide—Interstitial lung disease—Methotrexate—bone cancer	0.000365	0.00955	CcSEcCtD
Flutamide—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00036	0.0101	CbGpPWpGaD
Flutamide—CYP1A1—Estrogen metabolism—CYP3A4—bone cancer	0.000355	0.00992	CbGpPWpGaD
Flutamide—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000345	0.00965	CbGpPWpGaD
Flutamide—Herpes zoster—Methotrexate—bone cancer	0.000343	0.00897	CcSEcCtD
Flutamide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000332	0.0093	CbGpPWpGaD
Flutamide—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000332	0.00928	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—GNA11—bone cancer	0.000329	0.00919	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—EZH2—bone cancer	0.000327	0.00915	CbGpPWpGaD
Flutamide—CYP1A1—Xenobiotics—CYP3A4—bone cancer	0.000326	0.00912	CbGpPWpGaD
Flutamide—Herpes zoster—Epirubicin—bone cancer	0.000321	0.0084	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00032	0.00896	CbGpPWpGaD
Flutamide—CYP1A1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000314	0.00877	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000313	0.00876	CbGpPWpGaD
Flutamide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000313	0.00875	CbGpPWpGaD
Flutamide—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.000308	0.00805	CcSEcCtD
Flutamide—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000308	0.00861	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000305	0.00851	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000305	0.00851	CbGpPWpGaD
Flutamide—CYP1B1—Estrogen Receptor Pathway—JUN—bone cancer	0.000299	0.00835	CbGpPWpGaD
Flutamide—Herpes zoster—Doxorubicin—bone cancer	0.000297	0.00777	CcSEcCtD
Flutamide—CYP1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000291	0.00813	CbGpPWpGaD
Flutamide—Liver injury—Epirubicin—bone cancer	0.000288	0.00752	CcSEcCtD
Flutamide—Neoplasm malignant—Epirubicin—bone cancer	0.000283	0.00741	CcSEcCtD
Flutamide—Jaundice cholestatic—Epirubicin—bone cancer	0.000275	0.0072	CcSEcCtD
Flutamide—Ulcer—Methotrexate—bone cancer	0.000273	0.00714	CcSEcCtD
Flutamide—CYP1B1—Tryptophan metabolism—CYP3A4—bone cancer	0.000272	0.0076	CbGpPWpGaD
Flutamide—Rectal haemorrhage—Epirubicin—bone cancer	0.000268	0.007	CcSEcCtD
Flutamide—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000267	0.00746	CbGpPWpGaD
Flutamide—Liver injury—Doxorubicin—bone cancer	0.000266	0.00695	CcSEcCtD
Flutamide—AR—Generic Transcription Pathway—ZNF77—bone cancer	0.000264	0.00738	CbGpPWpGaD
Flutamide—Neoplasm malignant—Doxorubicin—bone cancer	0.000262	0.00685	CcSEcCtD
Flutamide—Pulmonary embolism—Methotrexate—bone cancer	0.000259	0.00676	CcSEcCtD
Flutamide—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000257	0.00718	CbGpPWpGaD
Flutamide—Ulcer—Epirubicin—bone cancer	0.000256	0.00669	CcSEcCtD
Flutamide—Jaundice cholestatic—Doxorubicin—bone cancer	0.000255	0.00666	CcSEcCtD
Flutamide—Cystitis noninfective—Methotrexate—bone cancer	0.000253	0.0066	CcSEcCtD
Flutamide—Cystitis—Methotrexate—bone cancer	0.00025	0.00653	CcSEcCtD
Flutamide—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000249	0.00695	CbGpPWpGaD
Flutamide—Rectal haemorrhage—Doxorubicin—bone cancer	0.000248	0.00648	CcSEcCtD
Flutamide—Pulmonary embolism—Epirubicin—bone cancer	0.000242	0.00632	CcSEcCtD
Flutamide—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000238	0.00665	CbGpPWpGaD
Flutamide—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000237	0.00663	CbGpPWpGaD
Flutamide—Ulcer—Doxorubicin—bone cancer	0.000237	0.00619	CcSEcCtD
Flutamide—Cystitis noninfective—Epirubicin—bone cancer	0.000236	0.00618	CcSEcCtD
Flutamide—Neoplasm—Methotrexate—bone cancer	0.000234	0.00611	CcSEcCtD
Flutamide—Bladder pain—Methotrexate—bone cancer	0.000234	0.00611	CcSEcCtD
Flutamide—Ecchymosis—Methotrexate—bone cancer	0.000234	0.00611	CcSEcCtD
Flutamide—Cystitis—Epirubicin—bone cancer	0.000234	0.00611	CcSEcCtD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000233	0.00651	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000232	0.00649	CbGpPWpGaD
Flutamide—Gynaecomastia—Methotrexate—bone cancer	0.000231	0.00605	CcSEcCtD
Flutamide—Blood urea increased—Epirubicin—bone cancer	0.000228	0.00597	CcSEcCtD
Flutamide—AHR—Adipogenesis—RB1—bone cancer	0.000228	0.00637	CbGpPWpGaD
Flutamide—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000226	0.00632	CbGpPWpGaD
Flutamide—Pulmonary embolism—Doxorubicin—bone cancer	0.000224	0.00585	CcSEcCtD
Flutamide—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00022	0.00615	CbGpPWpGaD
Flutamide—Bladder pain—Epirubicin—bone cancer	0.000219	0.00572	CcSEcCtD
Flutamide—Neoplasm—Epirubicin—bone cancer	0.000219	0.00572	CcSEcCtD
Flutamide—Ecchymosis—Epirubicin—bone cancer	0.000219	0.00572	CcSEcCtD
Flutamide—Cystitis noninfective—Doxorubicin—bone cancer	0.000219	0.00572	CcSEcCtD
Flutamide—CYP1B1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000217	0.00607	CbGpPWpGaD
Flutamide—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000217	0.00606	CbGpPWpGaD
Flutamide—Cystitis—Doxorubicin—bone cancer	0.000216	0.00565	CcSEcCtD
Flutamide—Diabetes mellitus—Methotrexate—bone cancer	0.000216	0.00564	CcSEcCtD
Flutamide—Blood urea increased—Doxorubicin—bone cancer	0.000211	0.00552	CcSEcCtD
Flutamide—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000208	0.00581	CbGpPWpGaD
Flutamide—Erythema—Cisplatin—bone cancer	0.000206	0.00538	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000205	0.00575	CbGpPWpGaD
Flutamide—Bladder pain—Doxorubicin—bone cancer	0.000202	0.00529	CcSEcCtD
Flutamide—Neoplasm—Doxorubicin—bone cancer	0.000202	0.00529	CcSEcCtD
Flutamide—Ecchymosis—Doxorubicin—bone cancer	0.000202	0.00529	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000202	0.00565	CbGpPWpGaD
Flutamide—Diabetes mellitus—Epirubicin—bone cancer	0.000202	0.00528	CcSEcCtD
Flutamide—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.0002	0.00559	CbGpPWpGaD
Flutamide—Ill-defined disorder—Cisplatin—bone cancer	0.000191	0.00499	CcSEcCtD
Flutamide—Anaemia—Cisplatin—bone cancer	0.00019	0.00498	CcSEcCtD
Flutamide—Hot flush—Epirubicin—bone cancer	0.000188	0.00491	CcSEcCtD
Flutamide—Increased appetite—Epirubicin—bone cancer	0.000187	0.00489	CcSEcCtD
Flutamide—Diabetes mellitus—Doxorubicin—bone cancer	0.000187	0.00488	CcSEcCtD
Flutamide—Menopausal symptoms—Epirubicin—bone cancer	0.000186	0.00486	CcSEcCtD
Flutamide—Malaise—Cisplatin—bone cancer	0.000186	0.00485	CcSEcCtD
Flutamide—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000185	0.00518	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—CDK4—bone cancer	0.000185	0.00517	CbGpPWpGaD
Flutamide—Leukopenia—Cisplatin—bone cancer	0.000184	0.00482	CcSEcCtD
Flutamide—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.000184	0.00514	CbGpPWpGaD
Flutamide—Dermatitis bullous—Epirubicin—bone cancer	0.000184	0.0048	CcSEcCtD
Flutamide—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000183	0.00512	CbGpPWpGaD
Flutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00018	0.00502	CbGpPWpGaD
Flutamide—CYP1B1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000178	0.00498	CbGpPWpGaD
Flutamide—Anxiety—Cisplatin—bone cancer	0.000175	0.00457	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000174	0.00455	CcSEcCtD
Flutamide—AR—Notch-mediated HES/HEY network—RB1—bone cancer	0.000174	0.00486	CbGpPWpGaD
Flutamide—Hot flush—Doxorubicin—bone cancer	0.000174	0.00454	CcSEcCtD
Flutamide—Discomfort—Cisplatin—bone cancer	0.000173	0.00453	CcSEcCtD
Flutamide—Increased appetite—Doxorubicin—bone cancer	0.000173	0.00452	CcSEcCtD
Flutamide—Menopausal symptoms—Doxorubicin—bone cancer	0.000172	0.0045	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000172	0.00481	CbGpPWpGaD
Flutamide—Dermatitis bullous—Doxorubicin—bone cancer	0.00017	0.00444	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000169	0.00442	CcSEcCtD
Flutamide—Oedema—Cisplatin—bone cancer	0.000168	0.00439	CcSEcCtD
Flutamide—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.000167	0.00468	CbGpPWpGaD
Flutamide—Thrombocytopenia—Cisplatin—bone cancer	0.000165	0.0043	CcSEcCtD
Flutamide—Skin disorder—Cisplatin—bone cancer	0.000163	0.00427	CcSEcCtD
Flutamide—Anorexia—Cisplatin—bone cancer	0.00016	0.00419	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000158	0.00413	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000158	0.00413	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.00015	0.00418	CbGpPWpGaD
Flutamide—Erectile dysfunction—Methotrexate—bone cancer	0.000149	0.0039	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000149	0.00417	CbGpPWpGaD
Flutamide—Photosensitivity reaction—Methotrexate—bone cancer	0.000148	0.00387	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000147	0.0041	CbGpPWpGaD
Flutamide—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000146	0.00382	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000146	0.00382	CcSEcCtD
Flutamide—Decreased appetite—Cisplatin—bone cancer	0.000146	0.00382	CcSEcCtD
Flutamide—Drowsiness—Methotrexate—bone cancer	0.000145	0.00378	CcSEcCtD
Flutamide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000143	0.00401	CbGpPWpGaD
Flutamide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000143	0.004	CbGpPWpGaD
Flutamide—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000141	0.00395	CbGpPWpGaD
Flutamide—Photosensitivity reaction—Epirubicin—bone cancer	0.000139	0.00362	CcSEcCtD
Flutamide—Feeling abnormal—Cisplatin—bone cancer	0.000139	0.00362	CcSEcCtD
Flutamide—Haematuria—Methotrexate—bone cancer	0.000138	0.0036	CcSEcCtD
Flutamide—Hyperglycaemia—Epirubicin—bone cancer	0.000137	0.00358	CcSEcCtD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000136	0.0038	CbGpPWpGaD
Flutamide—AR—FOXA1 transcription factor network—JUN—bone cancer	0.000136	0.0038	CbGpPWpGaD
Flutamide—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000135	0.00379	CbGpPWpGaD
Flutamide—Drowsiness—Epirubicin—bone cancer	0.000135	0.00354	CcSEcCtD
Flutamide—AR—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000135	0.00377	CbGpPWpGaD
Flutamide—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000134	0.00374	CbGpPWpGaD
Flutamide—Jaundice—Epirubicin—bone cancer	0.000132	0.00345	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00013	0.00364	CbGpPWpGaD
Flutamide—Hepatitis—Methotrexate—bone cancer	0.00013	0.00339	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000129	0.00362	CbGpPWpGaD
Flutamide—Haematuria—Epirubicin—bone cancer	0.000129	0.00337	CcSEcCtD
Flutamide—Photosensitivity reaction—Doxorubicin—bone cancer	0.000128	0.00335	CcSEcCtD
Flutamide—AR—Gene Expression—ZNF77—bone cancer	0.000127	0.00355	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000127	0.00354	CbGpPWpGaD
Flutamide—Hyperglycaemia—Doxorubicin—bone cancer	0.000127	0.00331	CcSEcCtD
Flutamide—Drowsiness—Doxorubicin—bone cancer	0.000125	0.00327	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000125	0.0035	CbGpPWpGaD
Flutamide—CYP1B1—Tryptophan metabolism—MDM2—bone cancer	0.000125	0.00349	CbGpPWpGaD
Flutamide—Jaundice—Doxorubicin—bone cancer	0.000122	0.00319	CcSEcCtD
Flutamide—Hepatitis—Epirubicin—bone cancer	0.000122	0.00318	CcSEcCtD
Flutamide—Asthenia—Cisplatin—bone cancer	0.000121	0.00315	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00012	0.00337	CbGpPWpGaD
Flutamide—Oedema peripheral—Epirubicin—bone cancer	0.00012	0.00313	CcSEcCtD
Flutamide—Haematuria—Doxorubicin—bone cancer	0.000119	0.00312	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—JUN—bone cancer	0.000119	0.00333	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000118	0.00329	CbGpPWpGaD
Flutamide—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000117	0.00328	CbGpPWpGaD
Flutamide—AR—Regulation of Androgen receptor activity—JUN—bone cancer	0.000117	0.00327	CbGpPWpGaD
Flutamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000116	0.00325	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000115	0.00323	CbGpPWpGaD
Flutamide—Diarrhoea—Cisplatin—bone cancer	0.000115	0.00301	CcSEcCtD
Flutamide—Erythema—Methotrexate—bone cancer	0.000113	0.00295	CcSEcCtD
Flutamide—CYP1B1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000113	0.00315	CbGpPWpGaD
Flutamide—Hepatitis—Doxorubicin—bone cancer	0.000112	0.00294	CcSEcCtD
Flutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000111	0.0031	CbGpPWpGaD
Flutamide—Oedema peripheral—Doxorubicin—bone cancer	0.000111	0.00289	CcSEcCtD
Flutamide—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00011	0.00307	CbGpPWpGaD
Flutamide—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000109	0.00306	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.000109	0.00305	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000109	0.00304	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000108	0.00303	CbGpPWpGaD
Flutamide—Vomiting—Cisplatin—bone cancer	0.000107	0.00279	CcSEcCtD
Flutamide—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000107	0.00299	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000106	0.00296	CbGpPWpGaD
Flutamide—Rash—Cisplatin—bone cancer	0.000106	0.00277	CcSEcCtD
Flutamide—Dermatitis—Cisplatin—bone cancer	0.000106	0.00277	CcSEcCtD
Flutamide—Erythema—Epirubicin—bone cancer	0.000106	0.00276	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000105	0.00294	CbGpPWpGaD
Flutamide—Ill-defined disorder—Methotrexate—bone cancer	0.000105	0.00274	CcSEcCtD
Flutamide—Anaemia—Methotrexate—bone cancer	0.000104	0.00273	CcSEcCtD
Flutamide—AR—Androgen receptor signaling pathway—RB1—bone cancer	0.000104	0.00292	CbGpPWpGaD
Flutamide—Tension—Epirubicin—bone cancer	0.000104	0.00271	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000104	0.0029	CbGpPWpGaD
Flutamide—Nervousness—Epirubicin—bone cancer	0.000103	0.00269	CcSEcCtD
Flutamide—Malaise—Methotrexate—bone cancer	0.000102	0.00266	CcSEcCtD
Flutamide—Leukopenia—Methotrexate—bone cancer	0.000101	0.00264	CcSEcCtD
Flutamide—Nausea—Cisplatin—bone cancer	9.98e-05	0.00261	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—TP53—bone cancer	9.88e-05	0.00276	CbGpPWpGaD
Flutamide—Ill-defined disorder—Epirubicin—bone cancer	9.81e-05	0.00257	CcSEcCtD
Flutamide—Erythema—Doxorubicin—bone cancer	9.79e-05	0.00256	CcSEcCtD
Flutamide—Anaemia—Epirubicin—bone cancer	9.78e-05	0.00256	CcSEcCtD
Flutamide—Tension—Doxorubicin—bone cancer	9.6e-05	0.00251	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	9.56e-05	0.0025	CcSEcCtD
Flutamide—Malaise—Epirubicin—bone cancer	9.54e-05	0.00249	CcSEcCtD
Flutamide—Discomfort—Methotrexate—bone cancer	9.51e-05	0.00248	CcSEcCtD
Flutamide—Nervousness—Doxorubicin—bone cancer	9.51e-05	0.00248	CcSEcCtD
Flutamide—Leukopenia—Epirubicin—bone cancer	9.47e-05	0.00247	CcSEcCtD
Flutamide—CYP1B1—Biological oxidations—CYP3A4—bone cancer	9.47e-05	0.00265	CbGpPWpGaD
Flutamide—CYP1B1—Metapathway biotransformation—CYP3A4—bone cancer	9.34e-05	0.00261	CbGpPWpGaD
Flutamide—Confusional state—Methotrexate—bone cancer	9.3e-05	0.00243	CcSEcCtD
Flutamide—Hypertension—Epirubicin—bone cancer	9.13e-05	0.00239	CcSEcCtD
Flutamide—Ill-defined disorder—Doxorubicin—bone cancer	9.08e-05	0.00237	CcSEcCtD
Flutamide—Anaemia—Doxorubicin—bone cancer	9.05e-05	0.00236	CcSEcCtD
Flutamide—Thrombocytopenia—Methotrexate—bone cancer	9.03e-05	0.00236	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	9.03e-05	0.00252	CbGpPWpGaD
Flutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.98e-05	0.00251	CbGpPWpGaD
Flutamide—Anxiety—Epirubicin—bone cancer	8.97e-05	0.00235	CcSEcCtD
Flutamide—Skin disorder—Methotrexate—bone cancer	8.96e-05	0.00234	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	8.94e-05	0.00234	CcSEcCtD
Flutamide—AR—Generic Transcription Pathway—NR1I2—bone cancer	8.93e-05	0.0025	CbGpPWpGaD
Flutamide—Discomfort—Epirubicin—bone cancer	8.9e-05	0.00233	CcSEcCtD
Flutamide—AR—Androgen receptor signaling pathway—MDM2—bone cancer	8.9e-05	0.00249	CbGpPWpGaD
Flutamide—Malaise—Doxorubicin—bone cancer	8.83e-05	0.00231	CcSEcCtD
Flutamide—Anorexia—Methotrexate—bone cancer	8.79e-05	0.0023	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	8.78e-05	0.00246	CbGpPWpGaD
Flutamide—Leukopenia—Doxorubicin—bone cancer	8.76e-05	0.00229	CcSEcCtD
Flutamide—Confusional state—Epirubicin—bone cancer	8.7e-05	0.00227	CcSEcCtD
Flutamide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	8.63e-05	0.00241	CbGpPWpGaD
Flutamide—Oedema—Epirubicin—bone cancer	8.63e-05	0.00226	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	8.54e-05	0.00239	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	8.54e-05	0.00239	CbGpPWpGaD
Flutamide—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	8.52e-05	0.00238	CbGpPWpGaD
Flutamide—Thrombocytopenia—Epirubicin—bone cancer	8.45e-05	0.00221	CcSEcCtD
Flutamide—Hypertension—Doxorubicin—bone cancer	8.45e-05	0.00221	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	8.42e-05	0.00235	CbGpPWpGaD
Flutamide—Skin disorder—Epirubicin—bone cancer	8.38e-05	0.00219	CcSEcCtD
Flutamide—Insomnia—Methotrexate—bone cancer	8.34e-05	0.00218	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	8.34e-05	0.00233	CbGpPWpGaD
Flutamide—Anxiety—Doxorubicin—bone cancer	8.3e-05	0.00217	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	8.27e-05	0.00216	CcSEcCtD
Flutamide—Discomfort—Doxorubicin—bone cancer	8.23e-05	0.00215	CcSEcCtD
Flutamide—Anorexia—Epirubicin—bone cancer	8.23e-05	0.00215	CcSEcCtD
Flutamide—Somnolence—Methotrexate—bone cancer	8.2e-05	0.00214	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	8.19e-05	0.00229	CbGpPWpGaD
Flutamide—CYP1B1—Biological oxidations—GSTP1—bone cancer	8.1e-05	0.00226	CbGpPWpGaD
Flutamide—Confusional state—Doxorubicin—bone cancer	8.05e-05	0.0021	CcSEcCtD
Flutamide—Decreased appetite—Methotrexate—bone cancer	8.02e-05	0.0021	CcSEcCtD
Flutamide—Oedema—Doxorubicin—bone cancer	7.99e-05	0.00209	CcSEcCtD
Flutamide—CYP1B1—Metapathway biotransformation—GSTP1—bone cancer	7.99e-05	0.00223	CbGpPWpGaD
Flutamide—Fatigue—Methotrexate—bone cancer	7.95e-05	0.00208	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—CDK4—bone cancer	7.86e-05	0.0022	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—TP53—bone cancer	7.86e-05	0.0022	CbGpPWpGaD
Flutamide—Thrombocytopenia—Doxorubicin—bone cancer	7.82e-05	0.00204	CcSEcCtD
Flutamide—Insomnia—Epirubicin—bone cancer	7.81e-05	0.00204	CcSEcCtD
Flutamide—Skin disorder—Doxorubicin—bone cancer	7.76e-05	0.00203	CcSEcCtD
Flutamide—AR—Androgen receptor signaling pathway—JUN—bone cancer	7.73e-05	0.00216	CbGpPWpGaD
Flutamide—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	7.7e-05	0.00215	CbGpPWpGaD
Flutamide—Somnolence—Epirubicin—bone cancer	7.67e-05	0.00201	CcSEcCtD
Flutamide—Anorexia—Doxorubicin—bone cancer	7.61e-05	0.00199	CcSEcCtD
Flutamide—Feeling abnormal—Methotrexate—bone cancer	7.6e-05	0.00199	CcSEcCtD
Flutamide—Decreased appetite—Epirubicin—bone cancer	7.5e-05	0.00196	CcSEcCtD
Flutamide—Fatigue—Epirubicin—bone cancer	7.44e-05	0.00195	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	7.42e-05	0.00207	CbGpPWpGaD
Flutamide—Constipation—Epirubicin—bone cancer	7.38e-05	0.00193	CcSEcCtD
Flutamide—Insomnia—Doxorubicin—bone cancer	7.22e-05	0.00189	CcSEcCtD
Flutamide—Feeling abnormal—Epirubicin—bone cancer	7.11e-05	0.00186	CcSEcCtD
Flutamide—Somnolence—Doxorubicin—bone cancer	7.1e-05	0.00186	CcSEcCtD
Flutamide—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	7e-05	0.00196	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—BRAF—bone cancer	6.96e-05	0.00195	CbGpPWpGaD
Flutamide—Decreased appetite—Doxorubicin—bone cancer	6.94e-05	0.00181	CcSEcCtD
Flutamide—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	6.94e-05	0.00194	CbGpPWpGaD
Flutamide—Fatigue—Doxorubicin—bone cancer	6.89e-05	0.0018	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—RB1—bone cancer	6.84e-05	0.00191	CbGpPWpGaD
Flutamide—Constipation—Doxorubicin—bone cancer	6.83e-05	0.00179	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	6.69e-05	0.00187	CbGpPWpGaD
Flutamide—Asthenia—Methotrexate—bone cancer	6.62e-05	0.00173	CcSEcCtD
Flutamide—Feeling abnormal—Doxorubicin—bone cancer	6.58e-05	0.00172	CcSEcCtD
Flutamide—Pruritus—Methotrexate—bone cancer	6.53e-05	0.00171	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.51e-05	0.00182	CbGpPWpGaD
Flutamide—Diarrhoea—Methotrexate—bone cancer	6.31e-05	0.00165	CcSEcCtD
Flutamide—AR—Gene Expression—FUS—bone cancer	6.21e-05	0.00174	CbGpPWpGaD
Flutamide—Asthenia—Epirubicin—bone cancer	6.19e-05	0.00162	CcSEcCtD
Flutamide—CYP3A5—Biological oxidations—CYP3A4—bone cancer	6.17e-05	0.00173	CbGpPWpGaD
Flutamide—Pruritus—Epirubicin—bone cancer	6.11e-05	0.0016	CcSEcCtD
Flutamide—Dizziness—Methotrexate—bone cancer	6.1e-05	0.00159	CcSEcCtD
Flutamide—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	6.09e-05	0.0017	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—EGFR—bone cancer	6.08e-05	0.0017	CbGpPWpGaD
Flutamide—Diarrhoea—Epirubicin—bone cancer	5.91e-05	0.00154	CcSEcCtD
Flutamide—Vomiting—Methotrexate—bone cancer	5.86e-05	0.00153	CcSEcCtD
Flutamide—CYP1A1—Biological oxidations—CYP3A4—bone cancer	5.83e-05	0.00163	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—MDM2—bone cancer	5.83e-05	0.00163	CbGpPWpGaD
Flutamide—Rash—Methotrexate—bone cancer	5.82e-05	0.00152	CcSEcCtD
Flutamide—Dermatitis—Methotrexate—bone cancer	5.81e-05	0.00152	CcSEcCtD
Flutamide—Headache—Methotrexate—bone cancer	5.78e-05	0.00151	CcSEcCtD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	5.76e-05	0.00161	CbGpPWpGaD
Flutamide—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	5.75e-05	0.00161	CbGpPWpGaD
Flutamide—Asthenia—Doxorubicin—bone cancer	5.73e-05	0.0015	CcSEcCtD
Flutamide—Dizziness—Epirubicin—bone cancer	5.71e-05	0.00149	CcSEcCtD
Flutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	5.68e-05	0.00159	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—NDUFA12—bone cancer	5.67e-05	0.00159	CbGpPWpGaD
Flutamide—Pruritus—Doxorubicin—bone cancer	5.65e-05	0.00148	CcSEcCtD
Flutamide—Vomiting—Epirubicin—bone cancer	5.49e-05	0.00143	CcSEcCtD
Flutamide—Nausea—Methotrexate—bone cancer	5.48e-05	0.00143	CcSEcCtD
Flutamide—Diarrhoea—Doxorubicin—bone cancer	5.46e-05	0.00143	CcSEcCtD
Flutamide—Rash—Epirubicin—bone cancer	5.44e-05	0.00142	CcSEcCtD
Flutamide—Dermatitis—Epirubicin—bone cancer	5.44e-05	0.00142	CcSEcCtD
Flutamide—CYP1A2—Phase II conjugation—GSTP1—bone cancer	5.43e-05	0.00152	CbGpPWpGaD
Flutamide—Headache—Epirubicin—bone cancer	5.41e-05	0.00141	CcSEcCtD
Flutamide—Dizziness—Doxorubicin—bone cancer	5.28e-05	0.00138	CcSEcCtD
Flutamide—CYP3A5—Biological oxidations—GSTP1—bone cancer	5.28e-05	0.00148	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	5.26e-05	0.00147	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	5.26e-05	0.00147	CbGpPWpGaD
Flutamide—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	5.21e-05	0.00146	CbGpPWpGaD
Flutamide—Nausea—Epirubicin—bone cancer	5.13e-05	0.00134	CcSEcCtD
Flutamide—Vomiting—Doxorubicin—bone cancer	5.08e-05	0.00133	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—JUN—bone cancer	5.07e-05	0.00142	CbGpPWpGaD
Flutamide—Rash—Doxorubicin—bone cancer	5.04e-05	0.00132	CcSEcCtD
Flutamide—Dermatitis—Doxorubicin—bone cancer	5.03e-05	0.00132	CcSEcCtD
Flutamide—Headache—Doxorubicin—bone cancer	5e-05	0.00131	CcSEcCtD
Flutamide—CYP1A1—Biological oxidations—GSTP1—bone cancer	4.99e-05	0.00139	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—JUN—bone cancer	4.94e-05	0.00138	CbGpPWpGaD
Flutamide—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	4.92e-05	0.00138	CbGpPWpGaD
Flutamide—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	4.91e-05	0.00137	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.83e-05	0.00135	CbGpPWpGaD
Flutamide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	4.77e-05	0.00133	CbGpPWpGaD
Flutamide—Nausea—Doxorubicin—bone cancer	4.74e-05	0.00124	CcSEcCtD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	4.73e-05	0.00132	CbGpPWpGaD
Flutamide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	4.71e-05	0.00132	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—NT5C3A—bone cancer	4.7e-05	0.00131	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.66e-05	0.0013	CbGpPWpGaD
Flutamide—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	4.43e-05	0.00124	CbGpPWpGaD
Flutamide—AR—Gene Expression—NR1I2—bone cancer	4.3e-05	0.0012	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	4.27e-05	0.00119	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.2e-05	0.00117	CbGpPWpGaD
Flutamide—CYP2C19—Biological oxidations—GSTP1—bone cancer	4.08e-05	0.00114	CbGpPWpGaD
Flutamide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	4.02e-05	0.00113	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—EGFR—bone cancer	3.98e-05	0.00111	CbGpPWpGaD
Flutamide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.79e-05	0.00106	CbGpPWpGaD
Flutamide—CYP1A2—Biological oxidations—CYP3A4—bone cancer	3.72e-05	0.00104	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—NDUFA12—bone cancer	3.7e-05	0.00103	CbGpPWpGaD
Flutamide—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	3.67e-05	0.00103	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—NDUFA12—bone cancer	3.49e-05	0.000977	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	3.35e-05	0.000938	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	3.35e-05	0.000938	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—TP53—bone cancer	3.34e-05	0.000935	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.3e-05	0.000923	CbGpPWpGaD
Flutamide—CYP1A2—Biological oxidations—GSTP1—bone cancer	3.18e-05	0.000889	CbGpPWpGaD
Flutamide—AR—Gene Expression—EIF2S1—bone cancer	3.18e-05	0.000888	CbGpPWpGaD
Flutamide—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	3.14e-05	0.000877	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—NT5C3A—bone cancer	3.07e-05	0.000857	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—NT5C3A—bone cancer	2.9e-05	0.00081	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—NDUFA12—bone cancer	2.86e-05	0.0008	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.77e-05	0.000775	CbGpPWpGaD
Flutamide—AR—Gene Expression—EZH2—bone cancer	2.76e-05	0.000772	CbGpPWpGaD
Flutamide—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.45e-05	0.000686	CbGpPWpGaD
Flutamide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.42e-05	0.000677	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—NT5C3A—bone cancer	2.37e-05	0.000663	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—NDUFA12—bone cancer	2.23e-05	0.000623	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—ENO2—bone cancer	2.06e-05	0.000576	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—DHFR—bone cancer	1.91e-05	0.000534	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—NT5C3A—bone cancer	1.85e-05	0.000516	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—GNA11—bone cancer	1.79e-05	0.000499	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—NDUFA12—bone cancer	1.72e-05	0.000481	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—CYP3A4—bone cancer	1.62e-05	0.000453	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.61e-05	0.00045	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—NT5C3A—bone cancer	1.43e-05	0.000398	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—GSTP1—bone cancer	1.38e-05	0.000387	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—ENO2—bone cancer	1.34e-05	0.000375	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—ENO2—bone cancer	1.27e-05	0.000355	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—DHFR—bone cancer	1.25e-05	0.000348	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—DHFR—bone cancer	1.18e-05	0.000329	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—GNA11—bone cancer	1.16e-05	0.000326	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—GNA11—bone cancer	1.1e-05	0.000308	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CYP3A4—bone cancer	1.06e-05	0.000295	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—ENO2—bone cancer	1.04e-05	0.00029	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CYP3A4—bone cancer	9.97e-06	0.000279	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.92e-06	0.000277	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—DHFR—bone cancer	9.63e-06	0.000269	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—GSTP1—bone cancer	9.03e-06	0.000252	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—GNA11—bone cancer	9e-06	0.000252	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—GSTP1—bone cancer	8.53e-06	0.000238	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CYP3A4—bone cancer	8.16e-06	0.000228	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.12e-06	0.000227	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—ENO2—bone cancer	8.09e-06	0.000226	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—DHFR—bone cancer	7.5e-06	0.00021	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PTGS2—bone cancer	7.17e-06	0.000201	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—GNA11—bone cancer	7.01e-06	0.000196	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—GSTP1—bone cancer	6.98e-06	0.000195	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CYP3A4—bone cancer	6.36e-06	0.000178	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.33e-06	0.000177	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—ENO2—bone cancer	6.24e-06	0.000175	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—DHFR—bone cancer	5.79e-06	0.000162	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—GSTP1—bone cancer	5.44e-06	0.000152	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—GNA11—bone cancer	5.41e-06	0.000151	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PTGS2—bone cancer	4.68e-06	0.000131	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PTGS2—bone cancer	4.42e-06	0.000124	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—GSTP1—bone cancer	4.2e-06	0.000117	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PTGS2—bone cancer	3.62e-06	0.000101	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PTGS2—bone cancer	2.82e-06	7.88e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PTGS2—bone cancer	2.17e-06	6.08e-05	CbGpPWpGaD
